BUND FINANCE › Stocks › PFE
Pfizer Inc. (PFE)
NYSE · Stock price, chart and technical analysis
Data from Financial Modeling Prep · Nov 19, 2026, 4:01 PM New York time · may be delayed
Key stats
Quick technical read
- Price is -4.47% below its 50-day average.
- It is +1.93% above its 200-day average (long-term uptrend).
- It sits at 50% of its 52-week range (0% = low, 100% = high).
This describes price action; it is not a recommendation. The app also calculates RSI, MACD, the entry setup and 30+ indicators. How we calculate it
Fundamentals Annual
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | US$81.3B | US$101.2B | US$59.6B | US$63.6B | US$62.6B |
| Net income | US$22.0B | US$31.4B | US$2.1B | US$8.0B | US$7.8B |
| EPS (diluted) | 3.85 | 5.47 | 0.37 | 1.41 | 1.36 |
| Gross margin | 62.1% | 66.1% | 58.1% | 71.9% | 74.3% |
| Operating margin | 24.9% | 37.7% | 7.4% | 23.5% | 27.8% |
| Net margin | 27.0% | 31.0% | 3.6% | 12.6% | 12.4% |
| Free cash flow | US$29.9B | US$26.0B | US$4.8B | US$9.8B | US$9.1B |
| Total debt | US$37.0B | US$34.9B | US$70.8B | US$67.0B | US$67.4B |
| Cash | US$1.9B | US$416.0M | US$2.9B | US$1.0B | US$1.1B |
Compound annual growth: revenue -6.3% · net income -22.9% (4 years).
Valuation: today, its history and its sector
| Today | 5-year average | Sector median (Healthcare) | |
|---|---|---|---|
| P/E | 39.5x | 27.6x | 26.4x |
| EV / EBITDA | 15.3x | 13.6x | 16.3x |
| Operating margin | 23.8% | — | 3.6% |
| Net margin | 6.3% | — | -0.0% |
| Debt / equity | 1.29 | — | 0.58 |
Source: annual financial statements from Financial Modeling Prep. “Today” uses the current price and the last 4 quarters. The sector median uses U.S. companies above US$300M market cap. A multiple above or below its history or sector is not a recommendation.
About Pfizer Inc.
Pfizer Inc. is a global biopharmaceutical leader engaged in the research, development, production, marketing, and distribution of a wide array of medicinal and vaccine products worldwide. Its comprehensive portfolio addresses diverse therapeutic areas, including cardiovascular health and women's health, featuring key brands such as the Premarin family and Eliquis. The company also offers advanced biologics, small molecule drugs, immunotherapies, and biosimilars for various conditions, exemplified by Ibrance, Xtandi, and Retacrit. Furthermore, Pfizer provides sterile injectables, anti-infective agents, and a significant oral treatment for COVID-19, including Paxlovid. A substantial portion of…
Other stocks on BUND FINANCE
Not financial advice. BUND FINANCE publishes general information for educational purposes. Investing involves risk, including loss of capital. Legal notice